Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Selpercatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Confirms Para IV Patent for Selpercatinib (Retevmo) Capsules
    FDA Confirms Para IV Patent for Selpercatinib (Retevmo) Capsules

    11 Jul 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-for-selpercatinib-retevmo-capsules-38305.pdf

    FDA
    11 Jul 2024
    Share Share
    Lilly's Retevmo lands new accelerated approval for pediatric cancers
    Lilly's Retevmo lands new accelerated approval for pediatric cancers

    30 May 2024

    // FDA

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-selpercatinib-pediatric-patients-two-years-and-older-ret-altered

    FDA
    30 May 2024
    Share Share
    Lilly's Retevmo Ph 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer
    Lilly's Retevmo Ph 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer

    21 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-phase-3-results-in-ret-fusion-positive-non-small-cell-lung-cancer-and-ret-mutant-medullary-thyroid-cancer-both-published-in-the-new-england-journal-of-medicine-and-presented-in-a-presidential-sympo-301963757.html

    PR NEWSWIRE
    21 Oct 2023
    Share Share
    ESMO: Lilly drug drives major benefits in lung, thyroid cancers
    ESMO: Lilly drug drives major benefits in lung, thyroid cancers

    21 Oct 2023

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma/esmo-lillys-retevmo-drives-major-benefits-lung-thyroid-cancers-roche-bows-out-competition

    Angus Liu FIERCE PHARMA
    21 Oct 2023
    Share Share
    FDA Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo
    FDA Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo

    09 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231009665112/en

    BUSINESSWIRE
    09 Oct 2023
    Share Share
    Lilly’s Retevmo Shows Superior Survival in Phase III Thyroid Cancer Trial
    Lilly’s Retevmo Shows Superior Survival in Phase III Thyroid Cancer Trial

    23 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-demonstrates-superior-progression-free-survival-compared-to-approved-multikinase-inhibitors-in-ret-mutant-medullary-thyroid-cancer-301906139.html

    PR NEWSWIRE
    23 Aug 2023
    Share Share